Nabriva Therapeutics AG Analysis
Nabriva Therapeutics AG is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Nabriva Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Nabriva Therapeutics AG is worth, separate from its market price. There are two main types of Nabriva Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Nabriva Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Nabriva Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Nabriva Stock trading window is adjusted to America/New York timezone.
Nabriva |
Nabriva Stock Analysis Notes
The company has price-to-book ratio of 0.24. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nabriva Therapeutics recorded a loss per share of 19.67. The entity last dividend was issued on the 3rd of December 2020. The firm had 1:25 split on the 16th of September 2022. Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Nabriva Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people. To find out more about Nabriva Therapeutics AG contact Colin MD at 353 1 649 2000 or learn more at https://www.nabriva.com.Nabriva Therapeutics Investment Alerts
| Nabriva Therapeutics is not yet fully synchronised with the market data | |
| Nabriva Therapeutics has some characteristics of a very speculative penny stock | |
| Nabriva Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M). | |
| Nabriva Therapeutics AG currently holds about 20.04 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53. |
Nabriva Therapeutics Upcoming and Recent Events
| 2nd of August 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View |
Nabriva Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.55 M.Nabriva Profitablity
The company has Profit Margin (PM) of (1.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.29.Nabriva Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nabriva Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nabriva Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nabriva Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
George Talbot over a year ago Exercise or conversion by George Talbot of 155 shares of Nabriva Therapeutics subject to Rule 16b-3 | ||
Theodore Schroeder over a year ago Payment of 431 shares by Theodore Schroeder of Nabriva Therapeutics subject to Rule 16b-3 |
Nabriva Therapeutics Outstanding Bonds
Nabriva Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nabriva Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nabriva bonds can be classified according to their maturity, which is the date when Nabriva Therapeutics AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Nabriva Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |